Masonic Cancer Center, University of Minnesota
Why trials sponsored by Masonic Cancer Center, University of Minnesota stopped, in this sample of ClinicalTrials.gov.
17 stopped trials with a clear reason; 59% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| slow enrollment | 4 | 24% |
| other | 4 | 24% |
| funding or business | 3 | 18% |
| safety | 3 | 18% |
| drug or device supply | 2 | 12% |
| regulatory or ethics | 1 | 6% |
Where it ranks
- #2 of 88 sponsors by share of trials stopped for: safety (18%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- Remote Trial - Tobacco Product Standard (VLNC)
NCT06442384 · TERMINATED · drug or device supply
“Study determined to be not feasible at this time due to limited availability of study product and limited availability of study products in the marketplace.” - Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
NCT05123040 · TERMINATED · funding or business
“Sponsor terminated financial support” - MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT05708924 · TERMINATED · funding or business
“Product withdrawn from clinical development” - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
NCT02145039 · TERMINATED · other
“Replaced by another study.” - Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00903630 · TERMINATED · funding or business
“lack of funding” - Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00818649 · TERMINATED · safety
“Met protocol stop rule \[i.e., extreme toxicity\]” - Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
NCT00784524 · TERMINATED · slow enrollment
“Slow accrual” - Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
NCT00652899 · TERMINATED · safety
“Withdrawn due to toxicity” - Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
NCT00643240 · TERMINATED · slow enrollment
“Due to slow accrual” - Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
NCT00617929 · TERMINATED · other
“Replaced by another protocol” - Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
NCT00602446 · TERMINATED · slow enrollment
“Due to slow accrual of patients” - Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
NCT00376805 · TERMINATED · safety
“Withdrawn due to toxicity” - Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
NCT00276159 · TERMINATED · drug or device supply
“Drug was not available.” - MT2004-30: Tomotherapy for Solid Tumors
NCT00623077 · TERMINATED · other
“Replaced by another study” - Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
NCT00618696 · TERMINATED · other
“Replaced with another study” - Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00287859 · TERMINATED · slow enrollment
“Withdrawn due to low accrual” - Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
NCT00303719 · TERMINATED · regulatory or ethics
“IRB Study Closure”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.